We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Prestige Consumer (PBH) Brand-Building Efforts Solid, Costs High
Read MoreHide Full Article
Prestige Consumer Healthcare Inc. (PBH - Free Report) appears to be well-placed for growth due to its robust brand-building efforts, favorable consumer demand and the growing e-commerce business. Gains from these upsides were visible in the company’s fourth-quarter fiscal 2022 results, wherein the top and bottom lines beat the Zacks Consensus Estimate and grew year over year.
However, the company is facing cost and supply chain-related hurdles. However, this over-the-counter (“OTC”) health and personal care products provider offered an encouraging guidance for fiscal 2023.
Factors Working Well for Prestige Consumer
Prestige Consumer prides on having a strong portfolio of healthcare brands. It has been focused on areas with greater growth potential. On its fourth-quarter fiscal 2022 earnings call, management stated that its largest brands hold the top market share, with many of them leading by a broad margin. This reflects consumers’ trust in PBH’s brands and the company’s focus on brand building, which helps expand categories. On its fourth-quarter earnings call, management stated that its portfolio supports long-term organic sales growth of 2-3%. It expects to continue generating industry-leading cash flow, which helps it repay debt, lower cash interest expenses and drive profits. Further, management envisions long-term earnings per share (EPS) growth of 6-8%.
The company has undertaken several lucrative acquisitions to boost its portfolio. It acquired TheraTears and four other OTC consumer brands across the VMS and Cough & Cold categories from Akorn Operating Company LLC. This buyout, concluded in July 2021, contributed to Prestige Consumer’s fourth-quarter results. In North America OTC Healthcare, gains of about $16 million from the Akorn acquisition aided segmental growth. Management remains optimistic about TheraTears’ and Clear Eyes’ prospects in the long term. These have been helping PBH enhance its footing in the eye care space.
The company has been making multi-year e-commerce investments for a while now. It continues to see growth in the e-commerce channel, which is approaching 50% of the company’s sales (as of the end of fiscal 2022). The upside can be attributed to consumers’ growing shift to online shopping as well as the company’s constant investments in online content and digital marketing. With more consumers shifting to the online mode of shopping, the e-commerce channel is likely to remain strong and Prestige Consumer’s investments in this arena are likely to keep it well-placed.
Image Source: Zacks Investment Research
Cost Woes
Prestige Consumer is encountering hurdles related to supply-chain restrictions and cost inflation. The company expects to witness inflation and supply-chain hurdles in fiscal 2023. Management expects a gross margin of more than 56% in fiscal 2023 compared with 57.1% in fiscal 2022. The company is focused on undertaking price increases to combat inflation.
A Look at Q4 & Ahead
Prestige Consumer posted fourth-quarter fiscal 2022 adjusted earnings of 91 cents per share, which surpassed the Zacks Consensus Estimate of 89 cents. The bottom line advanced 15.2% from the 79 cents recorded in the year-ago period. Total revenues grew 12.3% to $266.9 million and beat the Zacks Consensus Estimate of $258 million. Excluding currency impacts and contributions from the Akorn buyout, revenues rose 5.9%. Revenues were backed by strength in key brands, with improved demand across certain categories, brands and channels that were hurt by the pandemic in the year-ago period (such as cold & cough products).
Prestige Consumer benefited from its vast brand portfolio and solid business strategy, which helped it register a double-digit increase in revenues, earnings and cash flows. Certain categories like travel, which were earlier impacted by the pandemic, performed well in the fourth quarter.
Based on a robust fiscal 2022 show, management expects fiscal 2023 to witness continued growth. Management anticipates organic sales growth in the range of 2-3%, backed by its brand-building efforts and pricing actions. It expects operating profit growth to be at or a little more than its rate of sales. The solid guidance is likely to keep helping the company lower debt and undertake other strategic capital utilization moves. For fiscal 2023, PBH anticipates revenues in the range of $1,120-$1,130 million compared with the $1,086.8 million reported in fiscal 2022. Also, it envisions adjusted EPS in the band of $4.18-$4.23 compared with the $4.06 recorded in fiscal 2022.
Shares of this Zacks Rank #3 (Hold) company have dropped 8.6% in the past six months compared with the industry’s decline of 30.2%.
The Zacks Consensus Estimate for Central Garden & Pet’s current financial-year sales and EPS suggests growth of 4.7% and 7.5%, respectively, from the year-ago reported figure. CENT has a trailing four-quarter earnings surprise of around 406%, on average.
Funko (FNKO - Free Report) , which designs, sources and distributes licensed pop culture products, carries a Zacks Rank #2 at present.
The Zacks Consensus Estimate for Funko’s current financial-year sales and EPS suggests growth of 26.8% and 31%, respectively, from the year-ago reported number. FNKO has a trailing four-quarter earnings surprise of 78.7%, on average.
GIII Apparel Group (GIII - Free Report) , which designs, sources and markets women's and men's apparel, currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for GIII Apparel’s current financial-year sales and EPS suggests growth of 12.9% and 10.4%, respectively, from the year-ago reported figure. GIII has a trailing four-quarter earnings surprise of 97.5%, on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Prestige Consumer (PBH) Brand-Building Efforts Solid, Costs High
Prestige Consumer Healthcare Inc. (PBH - Free Report) appears to be well-placed for growth due to its robust brand-building efforts, favorable consumer demand and the growing e-commerce business. Gains from these upsides were visible in the company’s fourth-quarter fiscal 2022 results, wherein the top and bottom lines beat the Zacks Consensus Estimate and grew year over year.
However, the company is facing cost and supply chain-related hurdles. However, this over-the-counter (“OTC”) health and personal care products provider offered an encouraging guidance for fiscal 2023.
Factors Working Well for Prestige Consumer
Prestige Consumer prides on having a strong portfolio of healthcare brands. It has been focused on areas with greater growth potential. On its fourth-quarter fiscal 2022 earnings call, management stated that its largest brands hold the top market share, with many of them leading by a broad margin. This reflects consumers’ trust in PBH’s brands and the company’s focus on brand building, which helps expand categories. On its fourth-quarter earnings call, management stated that its portfolio supports long-term organic sales growth of 2-3%. It expects to continue generating industry-leading cash flow, which helps it repay debt, lower cash interest expenses and drive profits. Further, management envisions long-term earnings per share (EPS) growth of 6-8%.
The company has undertaken several lucrative acquisitions to boost its portfolio. It acquired TheraTears and four other OTC consumer brands across the VMS and Cough & Cold categories from Akorn Operating Company LLC. This buyout, concluded in July 2021, contributed to Prestige Consumer’s fourth-quarter results. In North America OTC Healthcare, gains of about $16 million from the Akorn acquisition aided segmental growth. Management remains optimistic about TheraTears’ and Clear Eyes’ prospects in the long term. These have been helping PBH enhance its footing in the eye care space.
The company has been making multi-year e-commerce investments for a while now. It continues to see growth in the e-commerce channel, which is approaching 50% of the company’s sales (as of the end of fiscal 2022). The upside can be attributed to consumers’ growing shift to online shopping as well as the company’s constant investments in online content and digital marketing. With more consumers shifting to the online mode of shopping, the e-commerce channel is likely to remain strong and Prestige Consumer’s investments in this arena are likely to keep it well-placed.
Image Source: Zacks Investment Research
Cost Woes
Prestige Consumer is encountering hurdles related to supply-chain restrictions and cost inflation. The company expects to witness inflation and supply-chain hurdles in fiscal 2023. Management expects a gross margin of more than 56% in fiscal 2023 compared with 57.1% in fiscal 2022. The company is focused on undertaking price increases to combat inflation.
A Look at Q4 & Ahead
Prestige Consumer posted fourth-quarter fiscal 2022 adjusted earnings of 91 cents per share, which surpassed the Zacks Consensus Estimate of 89 cents. The bottom line advanced 15.2% from the 79 cents recorded in the year-ago period. Total revenues grew 12.3% to $266.9 million and beat the Zacks Consensus Estimate of $258 million. Excluding currency impacts and contributions from the Akorn buyout, revenues rose 5.9%. Revenues were backed by strength in key brands, with improved demand across certain categories, brands and channels that were hurt by the pandemic in the year-ago period (such as cold & cough products).
Prestige Consumer benefited from its vast brand portfolio and solid business strategy, which helped it register a double-digit increase in revenues, earnings and cash flows. Certain categories like travel, which were earlier impacted by the pandemic, performed well in the fourth quarter.
Based on a robust fiscal 2022 show, management expects fiscal 2023 to witness continued growth. Management anticipates organic sales growth in the range of 2-3%, backed by its brand-building efforts and pricing actions. It expects operating profit growth to be at or a little more than its rate of sales. The solid guidance is likely to keep helping the company lower debt and undertake other strategic capital utilization moves. For fiscal 2023, PBH anticipates revenues in the range of $1,120-$1,130 million compared with the $1,086.8 million reported in fiscal 2022. Also, it envisions adjusted EPS in the band of $4.18-$4.23 compared with the $4.06 recorded in fiscal 2022.
Shares of this Zacks Rank #3 (Hold) company have dropped 8.6% in the past six months compared with the industry’s decline of 30.2%.
Consumer Discretionary Stocks Worth a Look
Central Garden & Pet Company (CENT - Free Report) , a producer and distributor of various products for the lawn and garden and pet supplies markets, currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Central Garden & Pet’s current financial-year sales and EPS suggests growth of 4.7% and 7.5%, respectively, from the year-ago reported figure. CENT has a trailing four-quarter earnings surprise of around 406%, on average.
Funko (FNKO - Free Report) , which designs, sources and distributes licensed pop culture products, carries a Zacks Rank #2 at present.
The Zacks Consensus Estimate for Funko’s current financial-year sales and EPS suggests growth of 26.8% and 31%, respectively, from the year-ago reported number. FNKO has a trailing four-quarter earnings surprise of 78.7%, on average.
GIII Apparel Group (GIII - Free Report) , which designs, sources and markets women's and men's apparel, currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for GIII Apparel’s current financial-year sales and EPS suggests growth of 12.9% and 10.4%, respectively, from the year-ago reported figure. GIII has a trailing four-quarter earnings surprise of 97.5%, on average.